SION — Sionna Therapeutics Balance Sheet
0.000.00%
- $1.91bn
- $1.66bn
- 27
- 26
- 95
- 47
Annual balance sheet for Sionna Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Cash and Equivalents | |||
| Short Term Investments | |||
| Cash and Short Term Investments | 82.6 | 38.5 | 148 |
| Prepaid Expenses | |||
| Total Current Assets | 83.8 | 39.2 | 151 |
| Gross Property, Plant And Equipment | |||
| Accumulated Depreciation | |||
| Net Property, Plant And Equipment | 2.57 | 11.7 | 10.3 |
| Long Term Investments | |||
| Other Long Term Assets | |||
| Total Assets | 87.4 | 51.9 | 186 |
| Accounts Payable | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Total Current Liabilities | 8.25 | 8.04 | 10.4 |
| Total Long Term Debt | |||
| Total Debt | |||
| Total Other Liabilities | |||
| Total Liabilities | 8.25 | 17.8 | 19.1 |
| Redeemable Preferred Stock | |||
| Non Redeemable Preferred Stock | |||
| Common Stock | |||
| Additional Paid In Capital | |||
| Retained Earnings (Accumulated Deficit) | |||
| Other Equity | |||
| Total Equity | 79.1 | 34.2 | 167 |
| Total Liabilities & Shareholders' Equity | 87.4 | 51.9 | 186 |
| Total Common Shares Outstanding |